Myoclonus—characterized by sudden, brief, involuntary muscle jerks—is a common movement disorder feature in corticobasal syndrome (CBS). It serves as an important clinical sign that helps differentiate CBS from other atypical parkinsonian disorders and provides insight into the underlying neuroanatomical dysfunction. Myoclonus occurs in approximately 15-27% of CBS patients during their disease course.
-
Cortical Myoclonus
- Most common type in CBS
- Originates from dysfunction in the motor cortex
- Typically stimulus-sensitive (triggered by touch, sound, or visual stimuli)
- Often affects distal muscles (fingers, hands)
- Usually asymmetric, correlating with cortical pathology
-
Subcortical Myoclonus
- Less common than cortical myoclonus
- Originates from brainstem or spinal cord structures
- Often generalized or axial in distribution
-
Myoclonus-Ataxia Syndrome
- A subset of CBS patients present with myoclonus and cerebellar ataxia
- May indicate additional cerebellar involvement
- Can mimic other myoclonus disorders (e.g., opsoclonus-myoclonus)
¶ Distribution and Pattern
- Asymmetric: Reflects the characteristic asymmetric cortical involvement in CBS
- Upper limb predominance: Hands and fingers most commonly affected
- Focal to segmental: Typically remains localized but can progress
- Action-exacerbated: Myoclonus often worsens with voluntary movement
- May be superimposed with limb dystonia
A specific "myoclonus-predominant" phenotype has been described characterized by:
- Prominent action myoclonus with voluntary movement
- Often affecting upper limbs, sometimes superimposed with limb dystonia
- Low-amplitude action myoclonus that may resemble action tremor
- "Jerks contaminating all voluntary movements"
- May have initially normal DaT-SPECT imaging, making diagnosis challenging
- 15-27% of CBS patients experience myoclonus during disease course
- Cortical myoclonus accounts for approximately 70% of cases
- More common than in PSP (where myoclonus is rare)
- Less common than in Creutzfeldt-Jakob disease (where myoclonus occurs in >90%)
| Feature |
CBS |
PSP |
PD |
sCJD |
| Myoclonus prevalence |
15-27% |
<10% |
10-20% |
>90% |
| Distribution |
Focal/asymmetric |
Rare |
Focal |
Generalized |
| Stimulus-sensitive |
Common |
Rare |
Uncommon |
Common |
| Onset |
Early-mid |
Rare |
Variable |
Rapid |
Myoclonus in CBS results from dysfunction in the cortical-subcortical motor networks:
-
Motor Cortex Dysfunction
- Tau deposition in layer V pyramidal neurons
- Reduced cortical inhibition
- Hyperexcitability leading to myoclonic jerks
-
Thalamocortical Pathway Dysregulation
- Abnormal thalamic output to motor cortex
- Loss of inhibitory control
- Disorganized motor neuron firing
-
Brainstem Involvement
- Reticular formation dysfunction
- Enhanced startle reflexes
- Generalized myoclonus in severe cases
flowchart TD
A["Motor Cortex<br/>Layer V Neurons"] --> B["Tau Pathology<br/>CBS"]
A --> C["Reduced Inhibition"]
C --> D["Hyperexcitability"]
D --> E["Myoclonus<br/>Focal Jerks"]
F["Thalamus"] --> A
F --> G["Abnormal Output"]
G --> E
H["Brainstem<br/>Reticular Formation"] --> I["Enhanced Startle"]
I --> E
Surface EMG in CBS myoclonus shows:
- Non-rhythmic, short-duration bursts (20-40 ms)
- Silent periods appearing synchronously in muscles
- Transcranial magnetic stimulation typically shows normal motor evoked potentials
Levetiracetam
- Dose: 500-1500mg twice daily
- Efficacy: Variable response; may reduce myoclonus frequency
Clonazepam
- Dose: 0.5-2mg daily (typically at bedtime)
- Efficacy: First-line; may improve myoclonus and anxiety
- Side effects: Sedation, dizziness
Valproic Acid
- Dose: 500-1500mg daily
- Monitoring: Liver function, platelets
Treatment of myoclonus in CBS is often challenging. The myoclonus-dominant phenotype has been reported to be refractory to multiple treatments including:
- Levodopa (up to 1,250mg)
- Levetiracetam
- Clonazepam
For refractory cases, consider:
- Combination therapy
- Piracetam (2.4-4.8g daily)
- Zonisamide (100-400mg daily)
- 5-Hydroxytryptophan (100-300mg daily)
- Environmental safety: Padded helmets for fall protection
- Adaptive equipment: Modified utensils, dressing aids
- Occupational therapy: Safety assessments and compensatory strategies
Myoclonus in CBS has several clinical implications:
- Diagnostic value: Helps distinguish CBS from PSP (where myoclonus is rare)
- Phenotypic variation: May indicate a specific myoclonus-dominant subtype
- Functional impact: Can significantly impair daily activities
- Prognostic indicator: Refractory myoclonus may suggest more severe cortical involvement
¶ Cross-Reference with PSP and FTD
CBS shares significant clinical and pathological overlap with other frontotemporal lobar degeneration (FTLD) spectrum disorders:
- Progressive supranuclear palsy (PSP): While myoclonus is rare in PSP (<10%), cortical myoclonus can occur in PSP variants
- Frontotemporal dementia (FTD): Myoclonus may occur in FTD, particularly in cases with motor features
- Pick complex: The concept integrates FTD, CBS, and PSP as related conditions within the same neurodegenerative spectrum